GlassScriptPhysician profile
Ryan J Logue
NPI 1093178477
$29,869.55
in general payments reported to CMS, 2019-2025
34 companies · $21K in 2025
The $21K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.32 · 2020: $128 · 2021: $87.34 · 2022: $986 · 2023: $3,590 · 2024: $3,991 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $11K · Education: $360 · Travel and Lodging: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,900.00 |
| Food and Beverage | $11,191.06 |
| Education | $359.71 |
| Travel and Lodging | $144.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19,253.81 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,282.75 | 2020-2025 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $1,341.42 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $947.42 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $841.11 | 2022-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $699.47 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $649.55 | 2023-2025 | Glassia, Hyqvia |
| Grifols USA, LLC | $450.91 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Insmed, INC. | $317.72 | 2022-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $311.75 | 2019-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $297.32 | 2022-2025 | Tezspire |
| Abbvie INC. | $286.89 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $233.24 | 2023-2025 | Acthar |
| Janssen Pharmaceuticals, INC | $206.13 | 2022-2024 | Xarelto |
| Medical Device Business Services, INC. | $198.93 | 2023 | Na |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $193.42 | 2022-2024 | Yupelri |
| Inari Medical, INC. | $177.74 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Philips North America LLC | $157.42 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Gilead Sciences, INC. | $145.28 | 2023-2024 | Veklury |
| Viatris Specialty LLC | $108.63 | 2025 | Yupelri |
| Verona Pharma, INC. | $102.96 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Inogen, INC. | $93.07 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Novartis Pharmaceuticals Corporation | $87.89 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $69.14 | 2022-2025 | Zerbaxa, Recarbrio |
| Advanced Respiratory, INC | $68.68 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.93 | 2025 | |
| Astellas Pharma US INC | $44.45 | 2020-2022 | |
| Pfizer INC. | $37.49 | 2021-2025 | |
| Pulmonx Corporation | $36.55 | 2024-2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| La Jolla Pharmaceutical Company | $21.87 | 2024 | Giapreza |
| Sun Pharmaceutical Industries INC. | $20.42 | 2024 | |
| Electromed, INC. | $16.15 | 2025 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Logue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.